What every intensivist should know about Tocilizumab

Crit Care. 2021 Jul 27;25(1):262. doi: 10.1186/s13054-021-03696-1.

Authors

Daniel Andrea Hofmaenner¹, Pedro David Wendel Garcia¹, Christoph Camille Ganter¹, Silvio D Brugger², Philipp Karl Buehler¹, Sascha David³

Affiliations

¹ Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
² Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
³ Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. sascha.david@usz.ch.

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / pharmacokinetics*
Antibodies, Monoclonal, Humanized / pharmacology
COVID-19 / physiopathology
COVID-19 Drug Treatment*
Critical Care
Humans
Interleukin-6 / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
IL6 protein, human
Interleukin-6
tocilizumab